Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaboration Arrangement [Line Items]
Accounts receivable, net - related party			$ 6,066		$ 3,260
Total revenue			6,165	$ 4,790
Commercial Supply Revenue
Collaboration Arrangement [Line Items]
Total revenue			3,191	4,790
Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue			125
Collaborative Revenue
Collaboration Arrangement [Line Items]
Total revenue			2,750
Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue			99
CSL Vifor, Maruishi and CKDP Agreements [Member]
Collaboration Arrangement [Line Items]
Other contract Assets			0		0
Other contract liabilities			0		0
CSL Vifor Kapruvia [Member] | Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue			125
Maruishi Pharmaceutical Co., Ltd. [Member] | Clinical Compound Revenue
Collaboration Arrangement [Line Items]
Total revenue			99	0
CSL Vifor [Member]
Collaboration Arrangement [Line Items]
Accounts receivable, net - related party			6,066		$ 3,260
CSL Vifor [Member] | Commercial Supply Revenue
Collaboration Arrangement [Line Items]
Total revenue			3,191	4,790
CSL Vifor [Member] | Commercial Supply Revenue With No Associated Costs Of Goods Sold [Member]
Collaboration Arrangement [Line Items]
Revenue		$ 2,295
Cost of goods sold		$ 0
CSL Vifor [Member] | Commercial Supply Revenue With Associated Costs Of Goods Sold [Member]
Collaboration Arrangement [Line Items]
Revenue	$ 2,495
Cost of goods sold	$ 2,081		2,590
CSL Vifor [Member] | Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue				0
CSL Vifor [Member] | Collaborative Revenue
Collaboration Arrangement [Line Items]
Total revenue			2,750	$ 0
CSL Vifor [Member] | CSL Vifor Kapruvia [Member] | Royalty Revenue
Collaboration Arrangement [Line Items]
Total revenue			$ 125